Iovance Biotherapeutics

IOVA · NASDAQ

$14.86+$0.65 (+4.57%)TodayMarket closed · Oct 20, 7:58 PM ET

Prev close $14.21

About IOVA

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 975 full-time employees. The company went IPO on 2008-06-20. The firm is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its products include Amtagvi and Proleukin. Amtagvi is indicated for the treatment of adult patients with melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor. The company is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. Its TIL therapy includes melanoma, non-small cell lung cancer and gynecologic cancer.

Employees: 975
Headquarters: San Carlos, California
Listed: Jun 20, 2008
Sector: Health Care
Industry: Biotechnology
Website: iovance.com

Leadership

Iovance Biotherapeutics executives
Name	Title	Since	Age
Iain Dukes	—	2016	66
Frederick Vogt	—	—	51
Corleen Roche	—	—	59
Igor Bilinsky	—	—	52
Friedrich Graf Finckenstein	—	—	58
Daniel Kirby	—	—	53
Raj Puri	—	—	69
Athena Countouriotis	—	—	53
Ryan Maynard	—	—	55
Wayne Rothbaum	—	—	57
Michael Weiser	—	—	62
Wendy Yarno	—	—	70

Revenue by product and region

Fiscal year ended Dec 31, 2025: $263.50M total revenue

By product

Represents the information pertaining to Amtagvi (lifileucel), the first product within its autologous TIL cell therapy platform.$220.02M83.5%
Represents the information pertaining to Proleukin (aldesleukin), product used in the Amtagvi treatment regimen.$43.48M16.5%

By region

UNITED STATES$259.01M98.3%
Non-US$4.49M1.7%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Iovance Biotherapeutics suppliers and customers
Company	Relationship	Country	Correlation
Phio Pharmaceuticals PHIO	Supplier and customer	US	0.91
Cellectis ALCLS.PA	Supplier and customer	FR	0.87
WuXi AppTec Co H	Supplier and customer	CN	0.83
CryoPort CYRX	Supplier	US	0.82
Lonza Group LONN.SW	Supplier and customer	CH	0.64
Avid Bioservices CDMO	Supplier	US	0.55
Novartis NOVN.SW	Supplier and customer	CH	0.01
United States	Supplier and customer	US	—
University of South Florida	Supplier and customer	US	—
University of Texas M.D. Anderson Cancer Center	Supplier	US	—

Similar companies

Companies in the same industry as Iovance Biotherapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.